See the DrugPatentWatch profile for Amvuttra
Amvuttra, a treatment for transthyretin amyloidosis, received FDA approval on June 13, 2024 [1]. This approval marks the launch of the drug, developed by Lexington-based Alnylam Pharmaceuticals [2].
When did Amvuttra become available?
Amvuttra became available shortly after its FDA approval on June 13, 2024 [1].
What is Amvuttra used to treat?
Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults [1]. This condition is also known as hATTR-PN.
How does Amvuttra work?
Amvuttra is an RNA interference (RNAi) therapeutic that works by targeting and reducing the production of TTR protein in the liver [2]. By decreasing TTR levels, it aims to prevent the formation of amyloid deposits that damage nerves and organs.
How does Amvuttra compare to other ATTR treatments?
Amvuttra is a new option for patients with hereditary transthyretin-mediated amyloidosis [1]. Its efficacy and safety profile will be compared to existing treatments as it gains wider clinical use. Information regarding direct head-to-head comparisons will likely emerge as the drug's market presence grows.
What is the patent status for Amvuttra?
Information on the specific patent exclusivity for Amvuttra can be found through resources like DrugPatentWatch.com [3]. Patent expiration dates are crucial for determining when generic or biosimilar versions might enter the market.
What are the potential side effects of Amvuttra?
The most common side effects reported in clinical trials for Amvuttra included upper respiratory tract infections, injection site reactions, pain in joints, and dizziness [1]. Patients should discuss potential risks with their healthcare provider.
What clinical trials led to Amvuttra's approval?
Amvuttra's approval was based on data from the APOLLO-B trial, which evaluated the drug's effectiveness in patients with ATTR-CM [2]. This trial demonstrated a statistically significant benefit in the composite endpoint of cardiovascular death and cardiovascular hospitalization [2].